These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 27893416

  • 1. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
    Chang LS, Lo MH, Li SC, Yang MY, Hsieh KS, Kuo HC.
    Oncotarget; 2017 Jan 10; 8(2):2044-2052. PubMed ID: 27893416
    [Abstract] [Full Text] [Related]

  • 2. Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response.
    Shrestha S, Wiener H, Shendre A, Kaslow RA, Wu J, Olson A, Bowles NE, Patel H, Edberg JC, Portman MA.
    Circ Cardiovasc Genet; 2012 Jun 10; 5(3):309-16. PubMed ID: 22565545
    [Abstract] [Full Text] [Related]

  • 3. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array.
    Kuo HC, Chang JC, Kuo HC, Yu HR, Wang CL, Lee CP, Huang LT, Yang KD.
    Arthritis Rheumatol; 2015 Mar 10; 67(3):828-36. PubMed ID: 25470559
    [Abstract] [Full Text] [Related]

  • 4. Expression of Fc<gamma>Rs on monocytes among Kawasaki disease patients with coronary artery lesions.
    Xia Y, Tian X, Li Q, Wang G, Li C, Yang J.
    Int Immunopharmacol; 2017 Apr 10; 45():1-5. PubMed ID: 28147297
    [Abstract] [Full Text] [Related]

  • 5. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T, Ohara T, Muto T, Okumura A, Baba R, Koizumi Y, Yamagishi Y, Mikamo H, Daigo K, Hamakubo T.
    Front Immunol; 2021 Apr 10; 12():624802. PubMed ID: 33912155
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
    Arthritis Rheum; 2013 Mar 10; 65(3):805-14. PubMed ID: 23440694
    [Abstract] [Full Text] [Related]

  • 7. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
    Zheng X, Li J, Yue P, Liu L, Li J, Zhou K, Hua Y, Li Y.
    PLoS One; 2021 Mar 10; 16(3):e0248812. PubMed ID: 33764989
    [Abstract] [Full Text] [Related]

  • 8. Plasma Prostaglandin E2 Levels Correlated with the Prevention of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions Formation via CD40L in Kawasaki Disease.
    Kuo HC, Wang CL, Yang KD, Lo MH, Hsieh KS, Li SC, Huang YH.
    PLoS One; 2016 Mar 10; 11(8):e0161265. PubMed ID: 27525421
    [Abstract] [Full Text] [Related]

  • 9. The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease.
    Biezeveld M, Geissler J, Merkus M, Kuipers IM, Ottenkamp J, Kuijpers T.
    Clin Exp Immunol; 2007 Jan 10; 147(1):106-11. PubMed ID: 17177969
    [Abstract] [Full Text] [Related]

  • 10. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S.
    Ther Apher Dial; 2015 Apr 10; 19(2):171-7. PubMed ID: 25257673
    [Abstract] [Full Text] [Related]

  • 11. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec 10; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 12. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
    Amano Y, Akazawa Y, Yasuda J, Yoshino K, Kojima K, Kobayashi N, Matsuzaki S, Nagasaki M, Kawai Y, Minegishi N, Ishida N, Motoki N, Hachiya A, Nakazawa Y, Yamamoto M, Koike K, Takeshita T.
    Pediatr Rheumatol Online J; 2019 Jul 03; 17(1):34. PubMed ID: 31269967
    [Abstract] [Full Text] [Related]

  • 13. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q, Zhou TF, Chen CH, Hua YM, Liu HM, Hong H, Zhang LY, Wu Q.
    Zhonghua Er Ke Za Zhi; 2005 Sep 03; 43(9):676-80. PubMed ID: 16191301
    [Abstract] [Full Text] [Related]

  • 14. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T, Ueno Y, Hasegawa M, Ishikawa Y, Matsubara T, Furukawa S.
    Rheumatology (Oxford); 2005 Mar 03; 44(3):314-7. PubMed ID: 15572393
    [Abstract] [Full Text] [Related]

  • 15. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
    Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K.
    J Pediatr; 2013 Jun 03; 162(6):1205-9. PubMed ID: 23290510
    [Abstract] [Full Text] [Related]

  • 16. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
    Pediatr Neonatol; 2014 Oct 03; 55(5):387-92. PubMed ID: 24636168
    [Abstract] [Full Text] [Related]

  • 17. Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy.
    Sapountzi E, Fidani L, Giannopoulos A, Galli-Tsinopoulou A.
    Pediatr Cardiol; 2023 Jan 03; 44(1):1-12. PubMed ID: 35908117
    [Abstract] [Full Text] [Related]

  • 18. Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease　- A Multicenter Retrospective Study.
    Okuma Y, Suda K, Nakaoka H, Katsube Y, Mitani Y, Yoshikane Y, Ichida F, Matsushita T, Shichino H, Shiraishi I, Abe J, Hiroe M, Yoshida T, Imanaka-Yoshida K.
    Circ J; 2016 Oct 25; 80(11):2376-2381. PubMed ID: 27746411
    [Abstract] [Full Text] [Related]

  • 19. HMGB1 gene polymorphism is associated with coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
    Ahn JG, Bae Y, Shin D, Nam J, Kim KY, Kim DS.
    Rheumatology (Oxford); 2019 May 01; 58(5):770-775. PubMed ID: 30535242
    [Abstract] [Full Text] [Related]

  • 20. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
    Kibata T, Suzuki Y, Hasegawa S, Matsushige T, Kusuda T, Hoshide M, Takahashi K, Okada S, Wakiguchi H, Moriwake T, Uchida M, Ohbuchi N, Iwai T, Hasegawa M, Ichihara K, Yashiro M, Makino N, Nakamura Y, Ohga S.
    Int J Cardiol; 2016 Jul 01; 214():209-15. PubMed ID: 27070994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.